自免BTK爆发,红斑狼疮重大突破

医曜
Dec 18, 2025

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。2025年堪称BTK抑制剂的“自免元年”。继今年8月底赛诺菲BTK抑制剂Rilzabrutinib获FDA批准、正式用于治疗原发免疫性血小板减少症(ITP)后,诺华同类药物Remibrutinib也于10月1日斩获FDA批准,适应症为接受H1抗组胺药治疗后仍有症状的成人慢性自发性荨麻疹(CSU)。两款BTK抑制剂在自免领域的连续获批,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10